We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Asklepios BioPharmaceutical and Selecta Biosciences announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia ...